A case of severe pityriasis rubra pilaris with a dramatic response to apremilast
暂无分享,去创建一个
[1] K. Peris,et al. Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.
[2] J. Uitto,et al. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients. , 2016, JAMA dermatology.
[3] A. Kaye,et al. Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast , 2016 .
[4] A. Qureshi,et al. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. , 2014, JAMA dermatology.
[5] A. Palfreeman,et al. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast , 2013, Drug design, development and therapy.
[6] Philip R. Cohen,et al. Pityriasis rubra pilaris: a review of diagnosis and treatment. , 1989, Journal of the American Academy of Dermatology.